MOG

MOG

MOG Overview

Molecule Name
Myelin-oligodendrocyte glycoprotein
Synonyms
MOG,BTN6,BTNL11,MOGIG2,NRCLP7,Myelin oligodendrocyte glycoprotein
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
NRCLP7,Myelin-oligodendrocyte glycoprotein,MOG,Myelin Oligodendrocyte Glycoprotein,MOG Ig-AluB,MOG Alpha-5,MOG AluA,MOG AluB,BTNL11,MOGIG2,BTN6
Background
Myelin oligodendrocyte glycoprotein (MOG), is a single-pass transmembrane glycoprotein of the immunoglobulin (Ig) superfamily. MOG is a myelin protein exclusively expressed in the CNS at the outermost surface of myelin sheaths and oligodendrocyte membranes. This makes MOG a potential target of cellular and humoral immune responses in inflammatory demyelinating diseases. Due to its late postnatal developmental expression, MOG is an important marker for oligodendrocyte maturation.

MOG Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
MOG autologous T-lymphocyte cell therapy (ImCyse)Phase 2 ClinicalImcyse Sa
Multiple Sclerosis
Details